New generation vaccines;Szczepionki nowej generacji

Medycyna Weterynaryjna

Volumn 62, Issue 8, 2006, Pages 855-859

  Truszczyński, Marian ^a,b   Pejsak, Zygmunt ^a  

^a NATIONAL VETERINARY RESEARCH INSTITUTE   (Poland)

^b NONE   (Poland)

Author keywords

Biotechnology; Novel vaccines

Indexed keywords

ANIMALIA; AVES; SUS SCROFA;

EID: 33747785343     PISSN: 00258628     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Babiuk L. A., Tikoo S. K.: Adenovirus as vector for delivering vaccines to mucosal surfaces. J. Biotechnol. 2000, 83, 105-113.
2. Babiuk L. A.: Broadening the approaches to developing more effective vaccines. Vaccine 1999, 17, 1587-1595.
3. Brochier B., Costy F., Pastoret P. P.: Elimination of fox rabies from Belgium using a recombinant vaccinia-rabies vaccine: an update. Vet. Microbiol. 1995, 46, 269-279.
4. Brochier B., Kieny M. P., Costy F., Coppenes P., Bauduin B., Lecocq J. P., Languet B., Chappuis G., Desmettre P., Afiademanyo K.: Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature 1991, 354, 520-522.
5. Capua I., Marangon S.: Vaccination for avian influenza in Asia. Vaccine 2004, 22, 4137-4138.
6. Commission Decision 2000/721/EC of 7 November 2000 on introducing vaccination to supplement the measures to control avian influenza in Italy and on specific movement control measures. Off. J. Eur. Comm. 2000, L 291, 33-36.
7. Council Directive 92/40/EEC of 19 May 1992 introducing Community measures for the control of avian influenza. Off. J. Eur. Comm. 1992, L 167, 1-16.
8. Drabner B., Guzman C.: Elicitation of predictable immune responses by using live bacterial vectors. Biomol. Eng. 2001, 17, 75-82.
9. th World Veterinary Poulty Congress, Istambul, Turkey 2005, Abstract No 099-25.
10. Grzesiowski P., Hryniewicz W., red. Gola̧b J., Jakóbisiak M., Lasek W.: Immunologia. PWN, Warszawa 2002.
11. Hu Y. C., Bentley W. E.: Enhancing yield of infectious bursal disease structural proteins in baculovirus expression systems: focus on media, protease inhibitors and dissolved oxygen. Biotechnology Prog. 1999, 15, 1065-1071.
12. Kit S., Sheppard M., Ichimura H., Kit M.: Second generation pseudorabies virus vasccine with deletions in thymidine kinase and glycoprotein genes. Am. J. vet. Res. 1987, 48, 780-793.
13. Koprowski H.: Vaccines and sera through plant biotechnology. Vaccine 2005, 23, 1757-1763.
14. Kowalski J., Gilbert S. A., van Drunen Little-van den Hurk S., van den Hurk J., Babiuk L. A., Zamb T.: Heat-shock promoter-driven synthesis of secreted bovine herpesvirus glycoproteins in transfected cells. Vaccine 1993, 11, 1100-1108.
15. Legocki A. B., Miedzinska K., Czaplińska M., Płucieniczak A., Wȩdrychowicz H.: Immunoprotective properties of transgenic plants expressing E2 glycoprotein from CSFV and cysteine protease from Fasciola hepatica. Vaccine 2005, 23, 1844-1846.
16. Liljeqvist S., Stahl S.: Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. J. Biotechnol. 1999, 73, 1-33.
17. Marciani D. J., Kensil C. R., Beltz G. A., Hung C. H., Cronier J., Aubert A.: Genetically-engineered subunit vaccine against feline leukemia virus: protective immune response in cats. Vaccine 1991, 2, 89-96.
18. Martin-Gallardo A., Fleischer E., Doyle S. A., Arumugham R., Collins P. L., Hildreth S. W., Paradiso P. R.: Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium. J. gen. Virol. 1993, 74, 453-458.
19. Mengeling W. L., Brockmeier S. L., Lager K. M., Vorwald A. C.: The role of biotechnologically engineered vaccines and diagnostics in pseudorabies (Aujeszky's disease) eradication strategies. Vet. Microbiol. 1997, 55, 49-60.
20. Moss B., Flexner C.: Vaccinia virus expression vectors. Annu. Rev. Immunol. 1987, 5, 305-324.
21. Murby M., Samuelsson E., Nguyen T. N., Mignard L., Power U., Binz H., Uhlen M., Stahl S.: Hydrophobicity engineering to increase solubility and stability of a recombinant protein from respiratory syncytial virus. Eur. J. Biochem. 1995, 230, 38-44.
22. Pastoret P. P., Blancou J., Vannier P., Verschueren red.: Veterinary Vaccinology. Elsevier, Amsterdam 1997.
23. Rogan D., Babiuk L. A.: Novel vaccines from biotechnology. Rev. sci. tech. Off. int. Epiz. 2005, 24, 159-174.
24. Ruitenberg K. M., Gilkerson J. R., Wellington J. E., Love D. N., Whalley J. M.: Equine herpesvirus 1 glycoprotein D expressed in Pichia pastoris is hyperglycosylated and elicits a protective immune response in the mouse model of EHV-1 disease. Virus Res. 2001, 79, 125-135.
25. Sheppard M.: Viral vectors for veterinary vaccines. Adv. Vet. Med. 1999, 41, 145-161.
26. Truszczyński M.: 70. Sesja Generalna OIE, ze szczególnym uwzglȩdnieniem problematyki naukowej. Medycyna Wet. 2002, 58, 815-818.
27. Van der Leek M. L., Feller J. A., Sorensen G., Isaacson W., Adams C., Borde D., Pfeiffer N., Tran T., Mover R., Gibbs E.: Evaluation of swine pox virus as a vaccine vector in pigs using an Aujeszky's disease (pseudorabies) virus gene insert coding for glycoproteins gp 50 and gp 63. Vet. Rec. 1994, 134, 13-18.
28. Van Oirschot J.: Diva vaccines that reduce virus transmission. J. Biotechnol. 1999, 73, 195-205.
29. Zakhartchouk A. N., Reedy P. S., Baxi M. K., Baca-Estrada M. E., Mechtali M., Babiuk L. A., Tikoo S. K.: Construction and characterization of E3 deleted bovine adenovirus type 3 expressing full lenghth and truncated from of bovine herpes virus glycoprotein D. Virology 1998, 250, 220-229.